New biomarker could translate to prognostic test for soft tissue sarcoma. . . A gene linked to susceptibility for a retinal cancer (retinoblastoma) may be the first independent prognostic biomarker in cases of soft tissue sarcoma (STS), according to a study published in the August 1 issue of Clinical Cancer Research. Researchers found that a reduction in the expression of the tumor suppressor gene pRb2/p130 can mean a higher risk of recurrence and death from STSs. A member of the retinoblastoma family of genes, pRb2/p130 regulates a portion of the cell cycle.

Subscribers: click here for the full story

Non-Subscribers: click here to subscribe

October 2008 - Table of Contents

DTTR October 2008 (full PDF issue)

Myriad Genetics May Spin Off Pharma Business

FDA Clears Third IVDMIA: XDx’s AlloMap

Nanogen to Merge With French Diagnostics Company

Meridian Bioscience Inks Canadian Distribution Deal

Inside the Diagnostics Industry: Nanogen’s David Ludvigson on Mergers, Markets, and Microarrays

New Gene Variant Linked to Prostate Cancer Risk

Protein Variant Predicts Chemotherapy Response

Pathwork Diagnostics Raises $20 Million

Pall Corporation Acquires GeneSystems

Physicians Frustrated by CMS’s Quality Reporting Initiative Feedback

IVD Stocks Down 6%; OraSure, Luminex Only Gainers

Biomarker for Soft Tissue Sarcoma